MyoKardia

Develops novel, small molecule therapeutics that address key clinical needs of patients with genetic heart diseases.

Launch date

Sep 2012

Employees

Market cap

Enterprise valuation

CAD17.9b (Public information from Oct 2020)

San Francisco California (HQ)

http://myokardia.com

https://twitter.com/myokardia https://www.linkedin.com/company/myokardia/

Authorizing premium user...